Header Logo

Connection

RACHELLE DOODY to Humans

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Humans.
RACHELLE DOODY
Connection Strength
1.233
Humans
  1. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
    View in: PubMed
    Score: 0.026
  2. Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
    View in: PubMed
    Score: 0.026
  3. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
    View in: PubMed
    Score: 0.025
  4. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
    View in: PubMed
    Score: 0.025
  5. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. J Prev Alzheimers Dis. 2023; 10(1):9-18.
    View in: PubMed
    Score: 0.023
  6. Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment? J Prev Alzheimers Dis. 2023; 10(3):344-345.
    View in: PubMed
    Score: 0.023
  7. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. Alzheimers Res Ther. 2022 11 29; 14(1):178.
    View in: PubMed
    Score: 0.023
  8. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
    View in: PubMed
    Score: 0.023
  9. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
    View in: PubMed
    Score: 0.020
  10. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. J Prev Alzheimers Dis. 2021; 8(2):151-160.
    View in: PubMed
    Score: 0.020
  11. Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. J Alzheimers Dis. 2021; 80(2):735-747.
    View in: PubMed
    Score: 0.020
  12. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. J Prev Alzheimers Dis. 2021; 8(4):393-395.
    View in: PubMed
    Score: 0.020
  13. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. J Neurochem. 2020 09; 155(2):120-136.
    View in: PubMed
    Score: 0.019
  14. Viewpoint: The Role of Futility Analyses in Alzheimer's Disease Clinical Trials. J Prev Alzheimers Dis. 2020; 7(1):7.
    View in: PubMed
    Score: 0.019
  15. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec; 35:1533317520918719.
    View in: PubMed
    Score: 0.019
  16. Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
    View in: PubMed
    Score: 0.019
  17. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
    View in: PubMed
    Score: 0.015
  18. Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech. J Prev Alzheimers Dis. 2017; 4(4):264-272.
    View in: PubMed
    Score: 0.015
  19. Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
    View in: PubMed
    Score: 0.015
  20. A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified. Stat Med. 2016 Apr 30; 35(9):1549-57.
    View in: PubMed
    Score: 0.014
  21. Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Clin Exp Neuropsychol. 2016; 38(5):516-26.
    View in: PubMed
    Score: 0.014
  22. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? Clin Neuropsychol. 2015; 29(7):1002-9.
    View in: PubMed
    Score: 0.014
  23. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 12; 21(6):450-459.
    View in: PubMed
    Score: 0.014
  24. Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. Psychol Assess. 2015 Dec; 27(4):1234-40.
    View in: PubMed
    Score: 0.014
  25. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460.
    View in: PubMed
    Score: 0.013
  26. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
    View in: PubMed
    Score: 0.012
  27. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 10 24; 369(17):1661.
    View in: PubMed
    Score: 0.012
  28. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
    View in: PubMed
    Score: 0.012
  29. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
    View in: PubMed
    Score: 0.012
  30. Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34(5-6):360-72.
    View in: PubMed
    Score: 0.011
  31. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013 May; 9(3):338-45.
    View in: PubMed
    Score: 0.011
  32. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012 Sep; 9(7):773-81.
    View in: PubMed
    Score: 0.011
  33. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
    View in: PubMed
    Score: 0.011
  34. Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012 Jul; 8(4):288-94.
    View in: PubMed
    Score: 0.011
  35. Binomial regression with a misclassified covariate and outcome. Stat Methods Med Res. 2016 Feb; 25(1):101-17.
    View in: PubMed
    Score: 0.011
  36. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012; 10(1-4):170-4.
    View in: PubMed
    Score: 0.011
  37. Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord. 2011; 32(5):362-6.
    View in: PubMed
    Score: 0.011
  38. Greater precision when measuring dementia severity: establishing item parameters for the Clinical Dementia Rating Scale. Dement Geriatr Cogn Disord. 2012; 34(2):128-34.
    View in: PubMed
    Score: 0.011
  39. Dementia staging across three different methods. Dement Geriatr Cogn Disord. 2011; 31(5):328-33.
    View in: PubMed
    Score: 0.010
  40. Global issues in drug development for Alzheimer's disease. Alzheimers Dement. 2011 Mar; 7(2):197-207.
    View in: PubMed
    Score: 0.010
  41. Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample. Dement Geriatr Cogn Disord. 2010; 30(6):486-91.
    View in: PubMed
    Score: 0.010
  42. Identifying amnestic mild cognitive impairment in primary care: a feasibility study. Clin Drug Investig. 2011; 31(7):483-91.
    View in: PubMed
    Score: 0.010
  43. [Clinical trials in AD]. Rinsho Shinkeigaku. 2010 Nov; 50(11):835.
    View in: PubMed
    Score: 0.010
  44. Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. J Nutr Health Aging. 2010 Apr; 14(4):299-302.
    View in: PubMed
    Score: 0.010
  45. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.009
  46. Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Neurology. 2009 Nov 03; 73(18):1514-5; author reply 1515-6.
    View in: PubMed
    Score: 0.009
  47. Dimebon as a potential therapy for Alzheimer's disease. CNS Spectr. 2009 Aug; 14(8 Suppl 7):14-6; discussion 16-8.
    View in: PubMed
    Score: 0.009
  48. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009; 28(1):63-9.
    View in: PubMed
    Score: 0.009
  49. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009 Mar; 5(2):122-4.
    View in: PubMed
    Score: 0.009
  50. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease. Alzheimers Dement. 2009 Mar; 5(2):133-6.
    View in: PubMed
    Score: 0.009
  51. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.009
  52. Cholinesterase inhibitors and memantine: best practices. CNS Spectr. 2008 Oct; 13(10 Suppl 16):34-5.
    View in: PubMed
    Score: 0.009
  53. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15.
    View in: PubMed
    Score: 0.008
  54. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.008
  55. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S21-5.
    View in: PubMed
    Score: 0.008
  56. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
    View in: PubMed
    Score: 0.008
  57. Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007; 24(5):375-9.
    View in: PubMed
    Score: 0.008
  58. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007 Jan; 22(1):99-107.
    View in: PubMed
    Score: 0.008
  59. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005; 20(2-3):198-208.
    View in: PubMed
    Score: 0.007
  60. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
    View in: PubMed
    Score: 0.007
  61. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
    View in: PubMed
    Score: 0.007
  62. A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
    View in: PubMed
    Score: 0.007
  63. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.006
  64. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004 Oct-Dec; 18(4):236-40.
    View in: PubMed
    Score: 0.006
  65. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005; 24(1-2):42-50.
    View in: PubMed
    Score: 0.006
  66. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 18(2):227-32.
    View in: PubMed
    Score: 0.006
  67. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
    View in: PubMed
    Score: 0.006
  68. Concern about Tominersen in Patients with Huntington's Disease. Reply. N Engl J Med. 2024 Mar 14; 390(11):1059.
    View in: PubMed
    Score: 0.006
  69. Gantenerumab in Early Alzheimer's Disease. Reply. N Engl J Med. 2024 Feb 29; 390(9):867.
    View in: PubMed
    Score: 0.006
  70. Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force. J Prev Alzheimers Dis. 2024; 11(5):1219-1227.
    View in: PubMed
    Score: 0.006
  71. Tominersen in Adults with Manifest Huntington's Disease. N Engl J Med. 2023 12 07; 389(23):2203-2205.
    View in: PubMed
    Score: 0.006
  72. WAIS-R factor structure in Alzheimer's disease patients: a comparison of alternative models and an assessment of their generalizability. Psychol Aging. 2003 Dec; 18(4):836-43.
    View in: PubMed
    Score: 0.006
  73. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
    View in: PubMed
    Score: 0.006
  74. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 17(1-2):1-4.
    View in: PubMed
    Score: 0.006
  75. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003; 64 Suppl 9:11-7.
    View in: PubMed
    Score: 0.006
  76. Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol. 2003 Jan; 18(1):19-32.
    View in: PubMed
    Score: 0.006
  77. Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). Alzheimers Dement. 2023 06; 19(6):2287-2297.
    View in: PubMed
    Score: 0.006
  78. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
    View in: PubMed
    Score: 0.006
  79. Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. J Alzheimers Dis. 2022; 85(1):31-45.
    View in: PubMed
    Score: 0.005
  80. Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(2):231-235.
    View in: PubMed
    Score: 0.005
  81. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.005
  82. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
    View in: PubMed
    Score: 0.005
  83. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 08; 56(9):1154-66.
    View in: PubMed
    Score: 0.005
  84. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.005
  85. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):449-54.
    View in: PubMed
    Score: 0.005
  86. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord. 2001 Jan-Mar; 15(1):1-9.
    View in: PubMed
    Score: 0.005
  87. Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(2):175-180.
    View in: PubMed
    Score: 0.005
  88. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2021; 8(3):306-312.
    View in: PubMed
    Score: 0.005
  89. Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000 Nov; 69(5):668-71.
    View in: PubMed
    Score: 0.005
  90. The issue of representation in brain research. Brain Cogn. 2000 Feb; 42(1):26-8.
    View in: PubMed
    Score: 0.005
  91. Alien limb sign. Adv Neurol. 2000; 82:135-45.
    View in: PubMed
    Score: 0.005
  92. The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis. 2020; 7(3):146-151.
    View in: PubMed
    Score: 0.005
  93. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999 Nov; 13 Suppl 2:S20-6.
    View in: PubMed
    Score: 0.005
  94. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
    View in: PubMed
    Score: 0.005
  95. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol. 1999 Apr; 9 Suppl 2:S69-77.
    View in: PubMed
    Score: 0.004
  96. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing. Nat Genet. 2019 03; 51(3):414-430.
    View in: PubMed
    Score: 0.004
  97. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999; 45 Suppl 1:23-32.
    View in: PubMed
    Score: 0.004
  98. Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999 Jan; 13(1):53-9.
    View in: PubMed
    Score: 0.004
  99. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. J Prev Alzheimers Dis. 2019; 6(3):169-173.
    View in: PubMed
    Score: 0.004
  100. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):263-5.
    View in: PubMed
    Score: 0.004
  101. Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
    View in: PubMed
    Score: 0.004
  102. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(3):171-174.
    View in: PubMed
    Score: 0.004
  103. Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997 Sep; 3(5):420-7.
    View in: PubMed
    Score: 0.004
  104. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 09; 49(9):1373-1384.
    View in: PubMed
    Score: 0.004
  105. Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997; 9(1):68-74.
    View in: PubMed
    Score: 0.004
  106. Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
    View in: PubMed
    Score: 0.004
  107. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
    View in: PubMed
    Score: 0.004
  108. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124.
    View in: PubMed
    Score: 0.004
  109. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 09; 16:89.
    View in: PubMed
    Score: 0.004
  110. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
    View in: PubMed
    Score: 0.004
  111. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
    View in: PubMed
    Score: 0.004
  112. Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. J Clin Exp Neuropsychol. 1996 Feb; 18(1):110-21.
    View in: PubMed
    Score: 0.004
  113. Validation of the Spanish version of the Baylor Profound Mental Status Examination. J Alzheimers Dis. 2016; 49(1):73-8.
    View in: PubMed
    Score: 0.004
  114. SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry. 1995 Oct; 152(10):1470-5.
    View in: PubMed
    Score: 0.003
  115. Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry. 1995 Sep; 152(9):1377-9.
    View in: PubMed
    Score: 0.003
  116. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimers Dement. 2016 Jan; 12(1):75-84.
    View in: PubMed
    Score: 0.003
  117. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(1):54-60.
    View in: PubMed
    Score: 0.003
  118. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.003
  119. Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2014; 41(4):1063-71.
    View in: PubMed
    Score: 0.003
  120. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
    View in: PubMed
    Score: 0.003
  121. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.003
  122. A reappraisal of localization theory with reference to aphasia. Part 1: Historical considerations. Brain Lang. 1993 Apr; 44(3):296-326.
    View in: PubMed
    Score: 0.003
  123. A reappraisal of localization theory with reference to aphasia. Part 2: Language theories from outside neurology. Brain Lang. 1993 Apr; 44(3):327-48.
    View in: PubMed
    Score: 0.003
  124. The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3.
    View in: PubMed
    Score: 0.003
  125. Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
    View in: PubMed
    Score: 0.003
  126. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2013; 33(2):517-23.
    View in: PubMed
    Score: 0.003
  127. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov 20; 2:e192.
    View in: PubMed
    Score: 0.003
  128. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.003
  129. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
    View in: PubMed
    Score: 0.003
  130. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
    View in: PubMed
    Score: 0.003
  131. A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(1):55-62.
    View in: PubMed
    Score: 0.003
  132. Olfactory copy number association with age at onset of Alzheimer disease. Neurology. 2011 Apr 12; 76(15):1302-9.
    View in: PubMed
    Score: 0.003
  133. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
    View in: PubMed
    Score: 0.003
  134. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
    View in: PubMed
    Score: 0.002
  135. Spasmodic dysphonia associated with palatal myoclonus. Ear Nose Throat J. 1990 Dec; 69(12):829-32.
    View in: PubMed
    Score: 0.002
  136. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
    View in: PubMed
    Score: 0.002
  137. Causes of aggressive behavior in patients with dementia. J Clin Psychiatry. 2010 Sep; 71(9):1145-52.
    View in: PubMed
    Score: 0.002
  138. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
    View in: PubMed
    Score: 0.002
  139. Consequences of aggressive behavior in patients with dementia. J Neuropsychiatry Clin Neurosci. 2010; 22(1):40-7.
    View in: PubMed
    Score: 0.002
  140. Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
    View in: PubMed
    Score: 0.002
  141. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
    View in: PubMed
    Score: 0.002
  142. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7.
    View in: PubMed
    Score: 0.002
  143. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92.
    View in: PubMed
    Score: 0.002
  144. Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
    View in: PubMed
    Score: 0.002
  145. Exploring self-neglect in older adults: preliminary findings of the self-neglect severity scale and next steps. J Am Geriatr Soc. 2008 Nov; 56 Suppl 2:S253-60.
    View in: PubMed
    Score: 0.002
  146. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug; 65(8):1091-5.
    View in: PubMed
    Score: 0.002
  147. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63.
    View in: PubMed
    Score: 0.002
  148. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
    View in: PubMed
    Score: 0.002
  149. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct; 42(14):1203-12.
    View in: PubMed
    Score: 0.002
  150. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34.
    View in: PubMed
    Score: 0.002
  151. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.002
  152. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.002
  153. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38.
    View in: PubMed
    Score: 0.002
  154. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
    View in: PubMed
    Score: 0.002
  155. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.002
  156. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
    View in: PubMed
    Score: 0.002
  157. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006; 4 Suppl A:S9-S24; quiz S25-S28.
    View in: PubMed
    Score: 0.002
  158. The making of a self-neglect severity scale. J Elder Abuse Negl. 2006; 18(4):13-23.
    View in: PubMed
    Score: 0.002
  159. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
    View in: PubMed
    Score: 0.002
  160. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005; 20(6):338-44.
    View in: PubMed
    Score: 0.002
  161. Self-reported awareness of performance in dementia. Brain Res Cogn Brain Res. 2005 Sep; 25(1):144-52.
    View in: PubMed
    Score: 0.002
  162. Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005; 20(2-3):133-9.
    View in: PubMed
    Score: 0.002
  163. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88.
    View in: PubMed
    Score: 0.002
  164. Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005 Mar; 53(3):389-96.
    View in: PubMed
    Score: 0.002
  165. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
    View in: PubMed
    Score: 0.002
  166. Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):22-31.
    View in: PubMed
    Score: 0.002
  167. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec; 60(12):1696-702.
    View in: PubMed
    Score: 0.002
  168. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.002
  169. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 03; 348(14):1333-41.
    View in: PubMed
    Score: 0.001
  170. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002 Feb 12; 58(3):433-7.
    View in: PubMed
    Score: 0.001
  171. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002; 13(1):8-12.
    View in: PubMed
    Score: 0.001
  172. Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec; 58(12):1985-92.
    View in: PubMed
    Score: 0.001
  173. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14; 57(3):481-8.
    View in: PubMed
    Score: 0.001
  174. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
    View in: PubMed
    Score: 0.001
  175. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15.
    View in: PubMed
    Score: 0.001
  176. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.001
  177. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan; 50(1):136-45.
    View in: PubMed
    Score: 0.001
  178. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997 Jul; 49(1):44-50.
    View in: PubMed
    Score: 0.001
  179. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1997 Jul; 49(1):70-5.
    View in: PubMed
    Score: 0.001
  180. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32.
    View in: PubMed
    Score: 0.001
  181. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:8-18.
    View in: PubMed
    Score: 0.001
  182. Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:19-21.
    View in: PubMed
    Score: 0.001
  183. Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:22-5.
    View in: PubMed
    Score: 0.001
  184. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 3:46-9.
    View in: PubMed
    Score: 0.001
  185. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol. 1996 Oct; 9(4):176-80.
    View in: PubMed
    Score: 0.001
  186. Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch Neurol. 1992 Jan; 49(1):87-92.
    View in: PubMed
    Score: 0.001
  187. Progressive nonfluent aphasia with dementia: a case report. J Geriatr Psychiatry Neurol. 1991 Oct-Dec; 4(4):236-40.
    View in: PubMed
    Score: 0.001
  188. Mental status assessment of insight and judgment. Clin Geriatr Med. 1989 Aug; 5(3):477-98.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.